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Summary
We report the first missense mutation in the mtDNA
gene for subunit II of cytochrome c oxidase (COX). The
mutation was identified in a 14-year-old boy with a
proximal myopathy and lactic acidosis. Muscle histo-
chemistry and mitochondrial respiratory-chain enzy-
mology demonstrated a marked reduction in COX ac-
tivity. Immunohistochemistry and immunoblot analyses
with COX subunit–specific monoclonal antibodies
showed a pattern suggestive of a primary mtDNAdefect,
most likely involving CO II, for COX subunit II (COX
II). mtDNA-sequence analysis demonstrated a novel het-
eroplasmic TrA transversion at nucleotide position
7,671 in CO II. This mutation changes a methionine to
a lysine residue in the middle of the first N-terminal
membrane-spanning region of COX II. The immunoblot
studies demonstrated a severe reduction in cross-reac-
tivity, not only for COX II but also for the mtDNA-
encoded subunit COX III and for nuclear-encoded sub-
units Vb, VIa, VIb, and VIc. Steady-state levels of the
mtDNA-encoded subunit COX I showed a mild reduc-
tion, but spectrophotometric analysis revealed a
dramatic decrease in COX I–associated heme a3 levels.
These observations suggest that, in the COX protein, a
structural association of COX II with COX I is necessary
to stabilize the binding of heme a3 to COX I.
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Introduction
Cytochrome c oxidase (COX) is the terminal electron
acceptor of the mitochondrial respiratory chain and cat-
alyzes the transfer of electrons from reduced cytochrome
c to molecular oxygen to form water (Capaldi 1990).
This enzyme complex comprises 13 subunits, 3 of which
(subunits I–III) constitute the catalytic core of the en-
zyme and are encoded by the mitochondrial genome, a
circular double-stranded 16.5-kb DNA molecule present
in multiple copies within mitochondria. The remaining
10 subunits are encoded by nuclear genes. The redox
centers involved in electron transfer are two heme A
moieties (a and a3) and two copper centers (CuA and
CuB). The heme a and the heme a3-CuB binuclear centers
are associated with COX I, whereas COX II contains
the CuA center (Tsukihara et al. 1996).
COX deficiency is the most commonly recognized res-
piratory-chain defect in childhood and is clinically het-
erogeneous with phenotypes including Leigh syndrome
and fatal and benign infantile myopathies (Di Mauro et
al. 1983, 1994; Rahman et al. 1996). To date, mtDNA
mutations have only been identified in CO III and CO
I: a microdeletion in CO III (Keightley et al. 1996) caus-
ing cramps and recurrent myoglobinuria, and point mu-
tations in CO III in two patients with encephalopathy
(see Manfredi et al. 1995; Hanna et al. 1998); and a
microdeletion in CO I in a patient with motor-neuron
disease (Comi et al. 1998). In other cases, combined
deficiency of COX and complex I of the respiratory
chain may be caused by large-scale rearrangements of
the mitochondrial genome, or by point mutations in-
volving mitochondrial tRNA genes (Holt et al. 1989;
Ciafaloni 1992). Failure to identify a mutation, even
after complete sequence analysis of all COX-subunit
genes in a number of patients, has led to the suggestion
that many cases of COX mutations may be due to ge-
netic defects in nuclear proteins involved in the assembly
of the COX enzyme complex (Adams et al. 1997; Lee
et al. 1998). Recently, mutations have been identified in
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the SURF-1 gene on chromosome 9 in patients with
Leigh syndrome and COX deficiency (Tiranti et al. 1998;
Zhu et al. 1998). The SURF-1 gene product is thought
to be involved in COX assembly or maintenance.
We have studied a boy with isolated COX deficiency
and have identified the first heteroplasmic point muta-
tion in the mitochondrially encoded gene for COX II.
We provide evidence that this mutation affects the as-
sembly or stability of the COX holoenzyme.
Patient and Methods
Clinical History
All studies were performed with the approval of the
ethics committee of the Royal Free Hospital National
Health Service Trust. A 14-year-old boy was referred for
investigation of a five-year history of muscle weakness
and fatigue. There was no family history of neuromus-
cular disease, the parents were healthy and unrelated,
and four younger siblings were all asymptomatic. On
examination, the patient was generally thin, but there
was no focal muscle wasting. There was mild weakness
of shoulder and pelvic-girdle musculature. Tendon re-
flexes were normal. There was no evidence of ophthal-
moplegia or retinopathy. Resting-blood lactate level was
elevated (4 mmol/l [reference range 0.9–1.8 mmol/l]) at
age 11 years but was normal (0.97 mmol/l) at age 14
years. Mild elevation of cerebrospinal fluid lactate (2.37
mmol/l) was noted at age 14 years. Results of magnetic
resonance imaging of the brain, echocardiography, elec-
trocardiogram, blood-creatine kinase, and investigations
of renal tubular function were all normal. Histochemical
staining of biopsied skeletal muscle, at age 11 years, had
revealed reduced COX activity, but biochemical assays
of other respiratory-chain complexes were not per-
formed. A further quadriceps-muscle biopsy was ob-
tained at age 14 years for detailed biochemical analysis,
after informed patient and parental consent was given.
Muscle Histochemistry and Immunohistochemistry
For histochemical studies, cryostat muscle samples cut
into 8-mm sections were stained, to demonstrate the ac-
tivities of COX and succinate dehydrogenase (SDH),
with use of standard methods (Filipe and Lake 1990;
Stoward and Pearse 1991). Sections were also stained
with the modified Gomori trichrome. A library of sub-
unit-specific mouse monoclonal antibodies was used to
identify COX subunits immunohistochemically in 10-
mm serial sections. Antibodies were directed against sub-
units I and II (mitochondrially encoded) and against sub-
units IV, Va, and VIc (nuclear encoded) (Taanman et al.
1996). Visualization was with the Strept-ABC (Dako)
technique, with 3,3′-diaminobenzidine hydrochloride.
Biochemical Studies
Polarographic and spectrophotometric enzyme assays
of respiratory-chain complexes were performed in iso-
lated mitochondria, as previously described by Cooper
et al. (1992). For spectral analysis of laser-flash photol-
ysis and recombination of carbon monoxide (CO), mi-
tochondria were prepared from 10–20 mg of skeletal
muscle (Darley-Usmar et al. 1983) and dissolved into
600 ml of 50 mM Tris/Cl, 10% ficoll, and 0.05% lauroyl
maltoside (pH 8); 500 ml were used for optical mea-
surements. The samples were reduced by addition of
sodium dithionite and gassed for 2 min with CO to
generate the CO-ferroheme a3 compound. Room-tem-
perature laser-flash photolysis of CO was performed as
previously described (Meunier and Rich 1998b). Short
actinic-light pulses were provided by a frequency-dou-
bled Nd-YAG laser. Optical signals of 430 and 445 were
recorded. Ten transients, at each wavelength, were signal
averaged and the data were plotted as DA at 430
nm versus time. The observed rate constants (Kobs)445
of CO recombination were obtained by the fit of ex-
ponential decays to the traces.
Immunoblot Analysis
A mitochondrial cell fraction was prepared by the
method of Darley-Usmar et al. (1983), scaled down for
a small sample size of ∼20 mg, and cellular proteins,
including mitochondrial membrane proteins, were ex-
tracted from myoblast and fibroblast cell pellets as de-
scribed by Taanman et al. (1997). Immunoblot analysis
was performed with use monoclonal antibodies against
COX subunits (Taanman et al. 1994, 1996), the flavo-
protein subunit of SDH (Marusich et al. 1997), the volt-
age-dependent anion channel (VDAC) (32HL; Calbio-
chem), core protein 1 of complex III, and the a subunit
of F1-ATP synthase. These last two monoclonal anti-
bodies were generated with bovine enzymes and chosen
after first being screened for specificity by reaction with
pure beef complex III or with ATP synthase, as well as
with bovine mitochondria. Their utility in immunohis-
tochemistry and western blotting with human enzymes
was confirmed with mitochondria isolated from human
skin fibroblasts.
mtDNA Amplification and Sequence Analysis
Total genomic DNA was extracted from blood, skel-
etal muscle biopsy, cultured myoblasts, and skin fibro-
blasts by established methods (Sambrook et al. 1989).
Sequence analysis was performed on muscle DNA. All
mitochondrial tRNA and COX genes were amplified, by
use of oligonucleotide primers with bacteriophage M13
tails. PCR products were sequenced with a Taq FS dye
primer cycle sequencing kit (PE Applied Biosystems) and
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were analyzed on an automated DNA sequencer (373A;
PE Applied Biosystems).
RFLP Detection of the Point Mutation
A mismatch PCR method was designed to detect the
mutant mtDNA molecule by creation of a restriction site
for the enzyme Tru 91 (Promega). The sequences of the
PCR primers used were as follows: (forward) 5′(7651)-
CTT TCA TGA TCA CGC CCT TA-(7670)3′ (mismatch
nucleotide italicized), and (reverse) 5′(7865)-AGG GAT
CGT TGA CCT CGT CT-(7846)3′. The PCR cycling
conditions used to amplify the target sequence were as
follows: 4 min denaturation at 94C followed by hot-
start addition of Taq polymerase, then 30 cycles of 30
s denaturation at 94C, 30 s annealing at 55C and 30
s extension at 72C. A final extension step of 10 min at
72C was performed after the last cycle. After digestion
with Tru 91, the 215-bp PCR product from the mutant
allele yielded two fragments, of 197 bp and 18 bp,
whereas the wild-type allele remained uncut.
Quantification of Mutant and Wild-Type PCR Products
The relative proportions of wild-type and mutant
mtDNA were determined by the addition of fluorescent
dUTP (PE Applied Biosystems) just before the final
(20th) cycle of the PCR, followed by Tru 91 restriction
digestion of the PCR product and separation onto a 5%
nondenaturing polyacrylamide gel. The fluorescent
products were analyzed with GENESCAN (PE Applied
Biosystems).
Single-Fiber PCR Analysis
The percentage of mutant mtDNA in individual fibers
was correlated with COX activity by use of a single-
fiber PCR assay, as previously described (Moraes and
Schon 1996). Muscle sections of 30 mm were stained for
COX activity and were fixed in 50% ethanol. Individual
muscle fibers were selected in accordance to COX stain-
ing (either positive or negative) and were microdissected
with a borosilicate microcapillary tube under an in-
verted-light microscope. The removed fiber segments
were placed in tubes containing 10 ml of water, centri-
fuged for 10 min, and then lysed at 65C for 1 h in a
solution containing 200 mM KOH and 50 mM DTT.
A neutralizing solution of 5 ml (900 mM Tris-HCl [pH
8.3] and 200 mM HCl) was added, and the samples
were then subjected to fluorescent mismatch PCR am-
plification and restriction digestion, as described above,
to determine the proportion of mutant mtDNA in single-
muscle fibers.
Studies in Cultured Cells
A primary myoblast culture was established, as de-
scribed by Yasin et al. (1977), from skeletal muscle biop-
sied when the patient was 14 years of age. Myoblasts
were grown in Dulbecco’s modified Eagle’s medium con-
taining 25 mM glucose and 4 mM L-glutamine and were
supplemented with 20% FCS, 2% detoxified chick em-
bryo extract, 1 mM sodium pyruvate, 200 mM uridine,
50 U/ml penicillin, and 50 mg/ml streptomycin. Cultured
skin fibroblasts were grown in the same medium, but
without chick embryo extract and with 10% rather than
20% FCS. Cells were cultured in a humidified 37C in-
cubator containing 8% CO2 in air. Cultured myoblasts
and fibroblasts were stained for COX activity and were
immunostained for COX subunit I, as previously de-
scribed (Taanman et al. 1997). COX and citrate synthase
assays were performed in freshly harvested cell pellets,
as described by Hartley et al. (1993).
Results
Morphological and Biochemical Studies
Muscle biopsy revealed severe COX deficiency in 97%
of fibers (fig. 1) with increased SDH staining, but showed
no frank ragged red fibers with the modified Gomori
trichrome stain. Muscle morphology and histochemistry
remained unchanged in two biopsies taken three years
apart, at age 11 years and 14 years, respectively. A defect
localized to COX was demonstrated by polarographic
and enzyme assays performed on the second biopsy (ta-
ble 1). Immunostaining of frozen muscle sections dem-
onstrated almost complete absence of COX II, with pre-
served immunostaining of subunits I, IV, and Va, but
with reduced staining of subunit VIc (fig. 1). Immunob-
lot analysis of a mitochondrial protein fraction, prepared
from skeletal muscle, confirmed the immunohistochem-
ical finding of a severe reduction of COX II compared
to controls (fig. 2). Further immunoblot analysis with
antibodies directed against other COX subunits dem-
onstrated reduced levels of all subunits investigated.
There was mild reduction of subunits I, IV, and Va, with
more marked reduction of subunits III, Vb, VIa (heart/
muscle isoform), VIb, and VIc (fig. 2). In addition, im-
munoblot analysis revealed increased steady-state levels
of other respiratory-chain and oxidative phosphoryla-
tion subunits (flavin protein of SDH, core 1 subunit of
complex III, and the a subunit of F1F0-ATP synthase).
Immunoblotting for VDAC was used to demonstrate
equal loading of samples (fig. 2).
Spectrophotometric Studies
To measure the COX I–associated heme a3 levels in
the muscle biopsies from controls and the COX-deficient
patient, mitochondria were prepared from 10–20 mg of
skeletal muscle. The samples were reduced by dithionite
and treated with CO, and CO flash-photolysis and re-
combination signals were monitored (Meunier and Rich
1998a). Figure 3 shows the optical signals obtained with
Figure 1 COX-activity staining (panels A and B) and COX immunohistochemical staining (panels C–H) in muscle. A = control;
B = patient; C = COX subunit II (control); D = COX subunit II (patient); E = COX subunit I (patient); F = COX subunit IV (patient); G =
COX subunit Va (patient); and H = COX subunit VIc (patient). Control sections stained for subunits I, IV, Va, and VIc appeared the same as
section C.
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Table 1
Polarography
Mitochondrial Oxygen Uptake
Substrate n Atoms (0/min/mg) Control Range
Glutamate/malate 26.5 53.3–312.0
Succinate 34.5 68.6–376.1
TMPD-ascorbatea 65.4 124–467.7
Respiratory-Chain Enzyme Assays
COX Complex nmol/min/mg Control Range
Complex I 167.1 (27.8–190.0)
Complex II/III 87.3 (18.3–234.3)
Complex IVb 2.4 (5.4–46.0)
Citrate synthase 1,745.92 (289.7–1,916.5)
a TMPD = N,N,N′,N′-tetramethyl-p-phenylenediamine.
b Units measured were k/min/mg.
Figure 2 Immunoblot analysis of skeletal muscle mitochondrial
fractions, from the patient (P) and two controls (C). Blots were de-
veloped with subunit-specific monoclonal antibodies to COX subunits,
the flavoprotein subunit of SDH (SDH Fp), core protein 1 of complex
III (core 1), the a subunit of F1-ATP synthase (F1-a), and VDAC.
mitochondria from a control and the patient. The traces
were biphasic. The fast component (K = 500–obs
) was the result of CO recombination with con-1600 s
taminating hemoglobin (or myoglobin). The slow com-
ponent ( ) arose from CO recombination1K = 60–65 sobs
with heme a3. The major component (∼95%) of the CO
recombination signal obtained with the COX-deficient
mitochondria was due to hemoglobin. In the control
trace, the main signal (∼65%) arose from CO reaction
with heme a3 ( ). The concentration of
1K =∼ 60 sobs
heme a3, estimated from the slow-component photolysis
signal by use of an extinction coefficient () of 113
mM1(cm1) at 430–445 nm, was ∼0.7 nM in the patient
sample and ∼11 nM in the control sample. heme a3 con-
tent was measured in a second control sample at a con-
centration of 6 nM (data not shown). It appeared, there-
fore, that CO-reactive heme a3 content was significantly
decreased in the mitochondria from the patient.
mtDNA studies
Southern blot and long-range PCR analyses excluded
the presence of large-scale rearrangements of mtDNA in
total genomic DNA extracted from the patient’s muscle
(data not shown). In view of the immunohistochemical
and immunoblot findings, we performed further analysis
of mtDNA (Rahman et al. 1997). Direct-sequence anal-
ysis revealed a novel thymine to adenine transversion at
nucleotide position 7,671 of mtDNA (T7671A), within
the gene encoding COX II (fig. 4), resulting in a missense
substitution of a lysine for a methionine at amino acid
residue 29 of the polypeptide. Other base changes from
the Anderson sequence (Anderson et al. 1981) were ei-
ther previously reported or were silent polymorphisms,
except for a previously unreported change in the D-loop
(G468A), which appeared homoplasmic in the sequence
chromatogram.
The T7671A mutation was present at 90% in DNA
extracted from both skeletal muscle biopsies (done at
age 11 years and age 14 years) but at only a low per-
centage in the patient’s blood (4.5%–6%). Single-fiber
PCR analysis in muscle samples revealed a significantly
higher mean mutant load in COX-negative muscle fibers
(81%, ) than in COX-positive fibers (45%,n = 13 n =
) ( , Mann-Whitney U test). The mutation was4 P = .01
not detected in the mother’s blood, nor in 110 normal
controls, nor in 15 individuals with mitochondrial dis-
ease in whom the underlying mutation was not known.
Cell-Culture Studies
No mutation was detected in cultured myoblasts or
fibroblasts at early cell passage, and staining for COX
activity and COX I immunoreactivity and spectropho-
tometric assays of COX activity were normal in these
cultures (data not shown). Immunoblot analysis of COX
subunits was also normal in cell protein extracts, pre-
pared from myoblast and fibroblast cell pellets (data not
shown)
Discussion
We describe a patient with isolated COX deficiency.
Biochemical, immunohistochemical, and immunoblot
analyses strongly suggested a mutation in the mtDNA
gene for COX II. A missense thymine to adenine trans-
version at nucleotide position 7,671 was identified in
CO II, and evidence for an etiologic role of this mutation
is presented. Sequencing of the remaining mtDNA mol-
ecule did not identify any other base changes of likely
pathogenic relevance.
Pathogenicity of the T7671A mutation is supported
by several lines of evidence. First, the mutation is het-
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Figure 3 Flash photolysis and recombination spectra of the CO-
ferroheme a3 compound of dissolved muscle mitochondria, from the
patient and a control. After reduction by sodium dithionite and treat-
ment with CO, laser-flash photolysis and recombination of CO was
monitored at nm versus time.430 445
Figure 4 Sequence chromatogram of mitochondrial COX II gene, in control sequence (top) and patient’s sequence (bottom). The arrow
indicates mutated base (adenine in place of wild-type thymine).
eroplasmic and present at high levels of mutant load
(90%) in skeletal muscle, the only clinically affected tis-
sue, but at very low levels of mutant load (∼6%) in
blood. Second, this genotype-phenotype correlation is
further supported by the single-fiber PCR studies, which
demonstrated significant correlation between mutant-
load level and COX activity in individual muscle fibers.
Third, the mutation alters an amino acid residue that is
relatively conserved in vertebrates (fig. 5). A noncharged
methionine residue is replaced by a basically charged
lysine, in the middle of the first N-terminal membrane-
spanning domain of COX II (Tsukihura et al. 1996).
Although the noncharged methionine residue is replaced
by other noncharged amino acid residues, in some spe-
cies, there is no known case in which it is substituted
for a charged amino acid residue. Fourth, the mutation
was not identified in a large number of ethnically
matched control subjects.
The mechanism of pathogenesis of the T7671A mu-
tation may be inferred from analogy with known yeast
mutations. Yeast studies have allowed classification of
COX mutations into two major groups: “activity” mu-
tations, and “assembly” mutations that affect the as-
sembly and/or stability of the COX holoenzyme (Meu-
nier and Rich 1998b). Activity mutations are generally
clustered in CO I and affect the electron-transfer func-
tion or the proton-pumping function of the enzyme.
COX II is anchored to the mitochondrial inner
membrane with an N-terminal helix-hairpin, whereas its
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Figure 5 Alignment of amino acid sequence in COX subunit II (mitochondrial genome sequence data obtained from gopher directory at
the Molecular Evolution and Organelle Genomics web site). The large box represents the first a-helical region in the bovine structure (Tsukihara
et al. 1996). The mutation in our patients involves amino acid residue 29.
Figure 6 Structure of monomer of bovine cytochrome c oxidase. The diagram shows the assembled bovine holoenzyme, with an arrow
indicating the site, in subunit II, that is mutated in our patient. The diagram was constructed with use of the data published by Tsukihara et
al. (1996) in the Quanta program.
large C-terminal hydrophilic domain, which protrudes
into the intermembrane space, contains the mixed-va-
lence binuclear CuA center and serves as the docking site
for cytochrome c (Capaldi 1990; Tsukihara et al. 1996).
The mutation, in our patient, converts an uncharged
amino acid residue in the highly conserved transmem-
brane segment of the COX II polypeptide into a basic
charged residue (fig. 6). The mutation is, therefore, pre-
dicted to interfere with the anchoring of COX II within
the mitochondrial membrane and to affect the assembly
or stability of the COX holoenzyme, rather than the
electron-transfer function of the subunit.
Studies of the assembly of COX in cultured human
cells have identified two assembly intermediates of the
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enzyme (Nijtmans et al. 1998). The first contains sub-
units I and IV. Subunits II and III are subsequently added,
together with subunits Va, Vb, VIb, VIc, VIIa or VIIb,
VIIc, and VIII. Finally, subunits VIa and VIIa or VIIb
are incorporated, to complete the assembly of the ho-
loenzyme. Results of the immunohistochemical and im-
munoblot analyses performed in our patient indicate
that the COX subunit II mutation identified here arrests
assembly of the COX holoenzyme after formation of the
first assembly intermediate, because the components of
this intermediate (subunits I and IV) are relatively pre-
served (as determined by immunoblotting) compared to
the other subunits investigated.
To determine the steady-state levels of subunit
I–associated heme a3, we followed the CO flash-pho-
tolysis and recombination signals spectrophotometri-
cally (Meunier and Rich 1998a). CO reacts with reduced
COX and produces the CO-ferroheme a3 compound.
CO can be photolyzed by a high-intensity short-duration
laser flash and will then recombine with the heme on a
millisecond time-scale. CO photolysis and rebinding can
be monitored optically and provide a sensitive means of
quantitation of COX. Because of the high photolysis
yield (195%) and the high  of the CO-COX compound
( at 430–445 nm), it is possible to1 1 = 113 mM (cm )
measure accurately COX content even in samples with
low levels of enzyme. Quantitation of COX can be hin-
dered by the presence of other hemoproteins, such as
hemoglobin or myoglobin, which also react with CO.
The optical signal induced by the binding of CO to these
hemoproteins overlaps that of the CO compound of
COX. However, the kinetics of CO recombination with
hemoglobin and myoglobin are significantly faster
( ) than the kinetics of CO recombination1K 1 500 sobs
with COX (∼60 s1), allowing the deconvolution of the
contribution of COX from hemoglobin and myoglobin,
especially when their concentration is low.
Immunohistochemical (fig. 1) and immunoblot (fig. 2)
analyses showed that the apo–subunit I levels in the pa-
tient were only marginally affected. In contrast, subunit
I–associated heme a3 levels were markedly decreased in
the patient (fig. 3). Taken together, our data suggest that
a structural association of subunit II with subunit I is
required to secure binding of the heme a3 prosthetic
group to apo-subunit I.
The surprisingly mild phenotype associated with the
mutation in our patient probably reflects the tissue dis-
tribution of the mutation. It is likely that skeletal muscle,
the only tissue affected clinically, is also the only tissue
with a mutant-load level above the threshold required
to reduce oxidative phosphorylation capacity. This
threshold is generally ∼85% for mitochondrial tRNA
mutations but may be lower for protein-coding muta-
tions (Hanna et al. 1998). The mutant load in skeletal
muscle in our patient has not changed over a period of
three years, and this is mirrored by clinical stability over
this same period. Stability of mutant load was also ob-
served in our patient with the stop mutation at nucle-
otide position 9,952 in the mitochondrial CO III gene
(Hanna et al. 1998), and may be a common feature of
mtDNA COX gene mutations. In contrast, mutant load
has frequently been observed to increase with time in
mtDNA tRNA mutations (Fu et al. 1996; Weber et al.
1997). The explanation for this is not clear. Demon-
stration of low levels of mutation in peripheral blood
cells from our patient may reflect clearance of mutation
in this rapidly dividing tissue, and this would be sup-
ported by the lower mutant load (4.5%) at 14 years
compared to a mutant load level of 6% at 11 years.
The absence of the mutation in maternal blood, with
the presence of mutation in both muscle and blood of
the patient, suggests that the mutation may have arisen
sporadically in early embryogenesis. However, the pos-
sibility of the presence of the mutation in the maternal
germline cannot be excluded.
The T7671A mutation was not detected in cultured
myoblasts, despite the high mutant load in mature skel-
etal muscle. The lack of mutation in satellite muscle cells
has previously been reported with another COX point
mutation (Hanna et al. 1998) and also with tRNA point
mutations (Fu et al. 1996; Weber et al. 1997). Absence
of the mutation from satellite cells has potential thera-
peutic implications. Previous studies have demonstrated
that, in patients with strong segregation of mutation
between satellite and mature muscle cells, induction of
muscle necrosis—either by bupivicaine local anaesthesia
(Clark et al. 1997) or by local trauma (Shoubridge et
al. 1997)—was followed by repopulation of the muscle
with cells containing only wild-type mtDNA. It remains
to be seen if induction of widespread muscle necrosis
will be a viable therapeutic option for such patients.
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